Esperion Therapeutics (NASDAQ:ESPR) was upgraded by Needham & Company LLC from a “buy” rating to a “strong-buy” rating in a research note issued on Thursday.
Other analysts have also issued reports about the company. BidaskClub lowered Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, December 7th. Zacks Investment Research raised Esperion Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, August 23rd. Jefferies Group reissued a “buy” rating and set a $85.00 target price on shares of Esperion Therapeutics in a report on Monday, August 21st. Chardan Capital increased their target price on Esperion Therapeutics from $20.00 to $75.00 and gave the stock a “neutral” rating in a report on Wednesday, December 6th. Finally, Northland Securities assumed coverage on Esperion Therapeutics in a report on Tuesday, August 29th. They set an “outperform” rating and a $72.00 target price on the stock. Eight equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $60.15.
Esperion Therapeutics (NASDAQ:ESPR) opened at $57.13 on Thursday. Esperion Therapeutics has a 12-month low of $10.71 and a 12-month high of $65.20.
Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($1.86) earnings per share for the quarter, missing the consensus estimate of ($1.79) by ($0.07). During the same period in the previous year, the company posted ($0.77) earnings per share. analysts predict that Esperion Therapeutics will post -7.3 EPS for the current year.
In related news, Director Nicole Vitullo sold 9,326 shares of the firm’s stock in a transaction dated Wednesday, December 6th. The stock was sold at an average price of $53.85, for a total value of $502,205.10. Following the sale, the director now directly owns 2,472 shares of the company’s stock, valued at $133,117.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 32.50% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in the stock. Meditor Group Ltd boosted its stake in Esperion Therapeutics by 305.5% in the third quarter. Meditor Group Ltd now owns 2,294,935 shares of the biopharmaceutical company’s stock valued at $115,022,000 after buying an additional 1,728,935 shares in the last quarter. BB Biotech AG boosted its stake in Esperion Therapeutics by 7.5% in the second quarter. BB Biotech AG now owns 1,513,542 shares of the biopharmaceutical company’s stock valued at $70,047,000 after buying an additional 105,000 shares in the last quarter. State Street Corp boosted its stake in Esperion Therapeutics by 264.6% in the second quarter. State Street Corp now owns 1,506,514 shares of the biopharmaceutical company’s stock valued at $69,721,000 after buying an additional 1,093,292 shares in the last quarter. FMR LLC boosted its stake in Esperion Therapeutics by 2.3% in the second quarter. FMR LLC now owns 1,338,588 shares of the biopharmaceutical company’s stock valued at $61,950,000 after buying an additional 30,000 shares in the last quarter. Finally, Discovery Capital Management LLC CT boosted its stake in shares of Esperion Therapeutics by 152.9% during the second quarter. Discovery Capital Management LLC CT now owns 965,059 shares of the biopharmaceutical company’s stock valued at $44,663,000 after purchasing an additional 583,529 shares in the last quarter. 92.28% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: “Esperion Therapeutics (ESPR) Upgraded at Needham & Company LLC” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2017/12/14/esperion-therapeutics-espr-upgraded-at-needham-company-llc.html.
Esperion Therapeutics Company Profile
Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.